

Targeting Cancer with 5 Key Spotlight Sessions on the Latest Therapy Breakthroughs

Cancer Vaccines 2016 returns to Central London this September for its 5th annual show

LONDON, ENGLAND, UNITED KINGDOM, July 18, 2016

/EINPresswire.com/ -- SMi's 5th annual [Cancer Vaccines](#) event will showcase 5 key spotlight sessions on the latest advances in vaccine development and cancer therapy breakthroughs when it returns to Central London this autumn.

1. Vaccine Design and Formulation

Highlights will include two case studies presented by Cancer Research UK on biomarker strategies; and

ImmunoCellular Therapeutics on dendritic cell immunotherapy.

2. Cancer Immunotherapy



The whole programme looks very exciting and I am looking forward to hearing about the vaccines of tomorrow."

NHS / Health Protection Scotland

With a focus on immunotherapy in cancer, Abzena's Senior VP of Scientific Operations will provide progressive insight into product design and in vitro assessment. This will be followed by a presentation from Northwest Biotherapeutic's CEO, who will give an update on new developments with novel personalised immune therapies.

3. Innovations in Vaccine Development

How critical are logistic issues? How can vaccines pass phase 3 trials? Where are the main pitfalls and can these be overcome? These will be just some of the questions answered by Dandrit DanDrit Biotech A/S.

The session will also include presentations on new clinical trial and proof of concept studies with RNA based vaccines from Biontech RNA Pharmaceuticals; peptide based cancer therapy with an academic overview from Nottingham Trent University; and T cell epitope identification with further insight into checkpoint blockade immune characterisation assays from Prolimmune.

4. Immune Check Point Inhibitors



SMi Presents the 5th Annual Event...  SMi

Cancer Vaccines

Holiday Inn Kensington Forum,
London, UK

21ST & 22ND
SEPT 2016

www.cancervaccinesevent.com

Cancer Vaccines 2016

Emphasising on omics and big data, Agenus take the next step in combining checkpoint modulators with patient specific vaccines for patient optimised treatment.

MSD go onto explain PD-1 Blockade, a broad spectrum anticancer therapy. Optimise your immunoncology treatment with strategic guidance on precision medicine, primary resistance and treatment failure.

5. Novel Cancer Immunotherapies

GU Malignancies have become an ideal platform for cancer immunotherapy development. Genentech give further insight into combination therapy, disease progression, and identify potential resistance mechanisms through gene expression profiling of responders and non-responders.

A detailed agenda and speaker line-up is available at www.cancervaccineevent.com

Cancer Vaccines 2016

5th Annual Conference: 21st & 22nd Sept | Interactive Workshop: 20th Sept
Holiday Inn Kensington Forum, London, UK

www.cancervaccineevent.com

Proudly Sponsored by: Abzena and Northwest Biotherapeutics

Contact Information:

For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk

To register for the conference, visit www.cancervaccineevent.com or contact Matthew Apps on

Tel: +44 (0)20 7827 6093 / Email: mapps@smi-online.co.uk

To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 /

Email: amalick@smi-online.co.uk

--- End ---

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Teri Arri
SMi Group
2078276000
[email us here](mailto:teriarri@smi-online.co.uk)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.